Tristan Anthony Peitz

Nessuna posizione attualmente

40 anni

Finance

Consumer Services

Process Industries

Profilo

Tristan Anthony Peitz worked as a Managing Director at Cohen Capital Management, Inc. (California) from 2010 to 2019.
He also served as an Independent Director at QSAM Biosciences, Inc. from 2017 to 2020.
Peitz received an undergraduate degree from the Stephen M.
Ross School of Business.

Precedenti posizioni note di Tristan Anthony Peitz

Società	Posizione	Fine
QSAM BIOSCIENCES, INC.	Direttore/Membro del Consiglio	09/12/2020
Cohen Capital Management, Inc. (California) Cohen Capital Management, Inc. (California) Investment ManagersFinance Cohen Capital Management, Inc. (CCM) is a registered independent wealth management firm headquartered in Corte Madera, California. The firm was founded by Jay A. Cohen in 1995. CCM manages clients’ cash balances, equity and fixed income portfolios on a fully disclosed basis primarily for high net-worth individuals.	Portfolio Manager-Fixed Income	01/07/2019

Vedi nel dettaglio l'esperienza di Tristan Anthony Peitz

Formazione di Tristan Anthony Peitz

Stephen M. Ross School of Business

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Tristan Anthony Peitz

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Cohen Capital Management, Inc. (California) Cohen Capital Management, Inc. (California) Investment ManagersFinance Cohen Capital Management, Inc. (CCM) is a registered independent wealth management firm headquartered in Corte Madera, California. The firm was founded by Jay A. Cohen in 1995. CCM manages clients’ cash balances, equity and fixed income portfolios on a fully disclosed basis primarily for high net-worth individuals.	Finance
QSAM Biosciences, Inc. QSAM Biosciences, Inc. Chemicals: AgriculturalProcess Industries QSAM Biosciences, Inc. engages in the provision of nuclear medicines for the treatment of cancer and related diseases and conditions. It also focuses on the development of its licensed radiopharmaceutical drug candidate, Samarium-153-DOTMP or CycloSam. The company was founded by Christopher M. Nelson, Douglas R. Baum and C. Richard Piazza on August 26, 2004 and is headquartered in Austin, TX.	Process Industries